Based on the evaluation of different downstream mTOR target proteins in 83 HL cases, increased mTOR activity was confirmed in more than 90% of HLs in our work, which was independent of HL subtype and clinical parameters. The gene discussed is MTOR; the disease is Hodgkins lymphoma.